Eli Lilly’s GLP-1 Litigation: Issues Related to Corporate Practice of Medicine and FDA Regulations

In a groundbreaking development for the digital health world, Eli Lilly, one of the world’s largest pharmaceutical companies, has filed lawsuits against a growing number of telehealth companies over the sale of compounded drugs Mounjaro and Zepbound, two popular GLP-1 medications. Nawa Lodin, Associate, Wilson Sonsini Goodrich & Rosati, and Lauren Petrin, Associate, Wiley Rein, discuss the background of compounding and when it is allowed under FDA regulations; the legal and regulatory issues at play in Eli Lilly’s lawsuits, including issues related to the corporate practice of medicine and FDA regulations; and key compliance considerations. Watch this episode: https://www.youtube.com/watch?v=XstaVQGtY24Essential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.

There are no comments yet.

Please log in to write the first comment.